A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans

Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives

(2013) TaeHun Kim et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans

(2013) Susan F. Hudachek et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat

(2013) Henry Pertinez et al.   PHARMACEUTICAL RESEARCH

Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions

(2012) David S. Hong et al.   CANCER TREATMENT REVIEWS

A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

(2012) K. Jhaveri et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting Hsp90--Who Benefits and Who Does Not

(2012) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

(2012) A Rostami-Hodjegan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic (PBPK) Modeling in Children

(2012) J S Barrett et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data

(2011) Leonid Kagan et al.   AAPS Journal

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

(2011) Simon Pacey et al.   CLINICAL CANCER RESEARCH

Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development

(2011) Feras Khalil et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

(2010) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

In Vitro Metabolism of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin in Human Liver Microsomes

(2010) N. Zheng et al.   DRUG METABOLISM AND DISPOSITION

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

(2010) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of Lysosomes in Limiting Drug Toxicity in Mice

(2010) R. A. Ndolo et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study

(2010) Joseph J. Sacco et al.   PLoS One

Physiologically Based Pharmacokinetic Modeling of Deltamethrin: Development of a Rat and Human Diffusion-Limited Model

(2010) Stephen J. Godin et al.   TOXICOLOGICAL SCIENCES

To scale or not to scale: the principles of dose extrapolation

(2009) Vijay Sharma et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

(2008) U. Banerji   CLINICAL CANCER RESEARCH

Enzymatic Reduction and Glutathione Conjugation of Benzoquinone Ansamycin Heat Shock Protein 90 Inhibitors: Relevance for Toxicity and Mechanism of Action

(2008) W. Guo et al.   DRUG METABOLISM AND DISPOSITION

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development

(2008) Andrea N Edginton et al.   Expert Opinion on Drug Metabolism & Toxicology